Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Luckily for you, we built StockStory to help you separate the good from the bad. Keeping that in mind, here are three cash-producing companies that don’t make the cut and some better opportunities instead.

Herbalife (HLF)

Trailing 12-Month Free Cash Flow Margin: 5%

With the first products sold out of the trunk of the founder’s car, Herbalife (NYSE: HLF) today offers a portfolio of shakes, supplements, personal care products, and weight management programs to help customers reach their nutritional and fitness goals.

Why Is HLF Not Exciting?

1. Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
2. Estimated sales growth of 3.7% for the next 12 months is soft and implies weaker demand
3. Earnings per share decreased by more than its revenue over the last three years, partly because it diluted shareholders

Herbalife is trading at $14.33 per share, or 5.8x forward P/E. Read our free research report to see why you should think twice about including HLF in your portfolio.

Lantheus (LNTH)

Trailing 12-Month Free Cash Flow Margin: 23%

Pioneering the "Find, Fight and Follow" approach to disease management, Lantheus Holdings (NASDAQGM:LNTH) develops and commercializes radiopharmaceuticals and other imaging agents that help healthcare professionals detect, diagnose, and treat diseases.

Why Do We Think Twice About LNTH?

1. Modest revenue base of $1.54 billion gives it less fixed cost leverage and fewer distribution channels than larger companies
2. Forecasted revenue decline of 6.3% for the upcoming 12 months implies demand will fall off a cliff
3. Efficiency has decreased over the last two years as its adjusted operating margin fell by 10.1 percentage points

At $80.01 per share, Lantheus trades at 14.6x forward P/E. If you’re considering LNTH for your portfolio, see our FREE research report to learn more.

Trupanion (TRUP)

Trailing 12-Month Free Cash Flow Margin: 5.2%

Born from a vision to help pet owners avoid economic euthanasia when faced with expensive veterinary bills, Trupanion (NASDAQ: TRUP) provides medical insurance for cats and dogs through data-driven, vertically-integrated products priced specifically for each pet's unique characteristics.

Why Does TRUP Give Us Pause?

1. Book value per share stagnated over the last five years, limiting its ability to leverage its balance sheet to make additional investments
2. Estimated book value per share growth of 3% for the next 12 months implies profitability will slow from its two-year trend
3. Negative return on equity shows that some of its growth strategies have backfired

Trupanion’s stock price of $25.77 implies a valuation ratio of 2.7x forward P/B. To fully understand why you should be careful with TRUP, check out our full research report (it’s free).

Stocks We Like More

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.